SciSparc Ltd.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- SciSparc Ltd. SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage specialty pharmaceutical company, develops cannabinoid-based therapies targeting central nervous system disorders and rare diseases; its core pipeline includes SCI-110, a proprietary palmitoylethanolamide (PEA) formulation for Tourette syndrome (currently in phase IIb trials), Alzheimer's disease and agitation (phase IIa completed), and related conditions; SCI-210 for autism spectrum disorder (randomized double-blind placebo-controlled trial commenced in early 2024) and status epilepticus; CannAmide, an anti-inflammatory and chronic pain solution; SCI-160 for pain management; SCI-150 for obesity and metabolic disorders; and preclinical candidates for obstructive sleep apnea and chronic pain. The company also operates a nutraceuticals segment through a controlled subsidiary that sells hemp-based products online, including hemp seed oil items such as gummies, oil capsules, gels, creams, detox pills, height pills, antibacterial creams, and anti-aging treatments, primarily via the Amazon.com Marketplace and manufactured in the United States. SciSparc Ltd. maintains strategic manufacturing partnerships, including with Procaps for SCI-110, CannAmide, and PEA oral tablets in softgel form; a collaboration with Clearmind Medicine Inc. since 2021 for combining PEA with 5-MeO-DMT in mental health treatments; and a phase IIa trial agreement with The Israeli Medical Center for Alzheimer's. Founded in 2004 and headquartered in Tel Aviv-Yafo, Israel, the company, formerly Therapix Biosciences Ltd. (name changed January 2021), primarily serves global markets in biotechnology and healthcare with a focus on unmet needs in neurology, psychiatry, and pain management; it listed on Nasdaq in 2017 and employs a lean team of two full-time staff led by CEO and CFO Oz Adler. Recent developments include positive top-line results from the 2024 phase IIa SCI-110 study in Tourette syndrome, demonstrating statistically significant tic severity reduction; a U.S. patent issuance in 2023 (No. 11,547,639) for Tourette treatments using CannAmide combinations; a November 2025 binding term sheet to acquire patents, trademarks, and IP for the MUSE endoscopic system from Xylo Technologies Ltd. (issuing shares for 19.99% ownership) to enter the $3 billion GERD device market via partnerships in North America, Europe, and Latin America; an October 2025 definitive agreement for a controlling interest (63.3 million shares plus contingents) in Miza III Ventures Inc., transferring its pharma portfolio and 51% nutraceuticals stake; and acquisition of 75% (potentially 84%) in Neurothera Labs Inc. along with a new quantum computing initiative for 3D protein modeling in drug discovery.
Company News
SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications
SciSparc Shares Halted On Circuit Breaker To The Downside, Stock Now Down -23.69%
SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies
SciSparc: Subsidiary NeuroThera Labs' CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company's Quantum Architecture
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
Neurothera Labs Inc. Announces Share Consolidation
NeuroThera Labs Engages Dr. Reuter Investor Relations
SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board
SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc's Stake Valued at Approximately C$30 Million
Neurothera Labs Inc. Closes Final Tranche of Non-Brokered Private Placement
NeuroThera Labs Inc. Closes First Tranche Of Non-Brokered Private Placement
SciSparc's Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination
NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination
SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome
SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome